Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
Bio2RDF identifier
NCT00255034
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00255034
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
baseline [clinicaltrials_vocabulary:baseline]
brief summary [clinicaltrials_vocabulary:brief-summary]
This is an Australian, ...... after completion of therapy.
brief title [clinicaltrials_vocabulary:brief-title]
Effects of 48 Weeks Versus 24 ...... e 3 (Study P04143)(TERMINATED)
clinical result [clinicaltrials_vocabulary:clinical-result]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2008-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-11-15T00:00:00Z
firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]
2009-06-04T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
chronic hepatitis C
pegylated interferon alfa-2b
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-03-30T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00255034
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase IV Study of Tailored The ...... reatment for HCV (GET-C Study)
org study id [clinicaltrials_vocabulary:org-study-id]
outcome [clinicaltrials_vocabulary:outcome]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
participant flow [clinicaltrials_vocabulary:participant-flow]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2008-06-01T00:00:00Z
reported events [clinicaltrials_vocabulary:reported-events]
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2005-02-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-03-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Recruitment targets were unachievable in the currently available population.
identifier
clinicaltrials:NCT00255034
title
Effects of 48 Weeks Versus 24 ...... e 3 (Study P04143)(TERMINATED)
@en